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An Overview of Pediatric CNS 
Malignancies
Neha Sharma and Deepti Sharma
Abstract
Central nervous system tumours are the most common solid tumours and 
second most common malignancy in pediatric age group. They are the leading 
cause of cancer related morbidity and mortality. It accounts for 3.5% of all deaths 
in the 1–14 years age group. Childhood central nervous system (CNS) tumors 
differ significantly from adult brain tumors in reference to their sites of origin, 
clinical presentation, tendency to disseminate early, histological features and 
their biological behaviour. Supratentorial tumors are more common in infants 
and children up to 3 years of age and again after age 10, whereas between ages 4 
and 10 infratentorial tumors are more common. The initial workup of patients 
with brain tumors must include a complete history, physical examination, imag-
ing and biopsy confirmation of primary. The management of pediatric brain 
tumours is important due to their high incidence, challenging aspects of surgery 
and high mortality. Many CNS malignancies, which were once universally fatal are 
now curable with multimodality approaches that integrate surgery, chemotherapy 
and radiotherapy. In this chapter, we will discuss these issues in detail and sum-
marize the ongoing efforts to reduce the morbidity and mortality in pediatric CNS 
tumours.
Keywords: CNS, pediatric, adjuvant, radiation therapy
1. Overview
Tumors of the central nervous system are the most common solid tumors in 
the pediatric age group and the second most common childhood malignancy. 
They are the leading cause of morbidity and mortality associated with cancer. 
Although it affects all ages, the incidence peaks among children between the 
ages of 3 and 7. In adults and older children, most tumours are supratentorial 
in location while in young children they are more commonly infratentorial 
in location [1].
2. Incidence
The incidence of childhood CNS tumor varies from 1.12 to 5.14 cases per 
100,000 individuals [2]. Based upon data from the Central Brain Tumor Registry 
of the United States (CBTRUS), the estimated incidence of primary non-malig-
nant and malignant CNS tumors for children and adolescents up to 19 years of 
age was 7.18 cases per 100,000 person-year in 2016 [3]. More than 100 different 
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histological subtypes of CNS tumours are recognized but their incidence varies 
with age. Incidence in Africa is around 11 per 10,00,000 and in Japan and Europe 
it ranges from 20 to 30 per 1,000,000. The male to female ratio is 1.25:1, as slightly 
higher frequency of medulloblastoma and CNS germinoma is seen in boys [4]. 
The most common histological subtypes along with location are mentioned below 
(Table 1).
3. Etiology and pathogenesis
Development of brain tumours occurs as a consequence of cellular genetic 
alterations that allow them to evade normal regulatory mechanisms and destruction 
by the immune system. These changes may be caused by an inherited or acquired 
(chemical, physical or biological neuro-carcinogens) cause. Overall, only a very 
small percentage of brain tumors can be ascribed to the effect of inherited inclina-
tion (Table 2). The different environmental factors involved and alleged typically 
involve ionizing radiation, non-ionizing radiation, N-nitroso compounds, viral 
infections (JC virus, cytomegalovirus, HIV, SV-40, varicella-zoster, chicken pox) 
and head injury [6].
Location Tumor type Relative frequency (%)  
in 0–17 years old
Supratentorial Pilocytic astrocytoma 23.5
Fibrillary astrocytoma 5
Ganglioganglioma 2.5
Dysembryoplastic neuroepithelial tumor 0.6
Desmoplastic infantile ganglioglioma 0.6
Choroid plexus papilloma 0.9
Ependymoma 3.8
Anaplastic ependymoma 3.8
Anaplastic astrocytoma 7.2
Glioblastoma 7.2
Supratentorial PNET 1.9
Choroid plexus carcinoma 0.6
Posterior fossa Medulloblastoma 16.3
ATRT 1.3
Pilocytic astrocytoma 23.5
Ependymoma 3.8
Brainstem glioma 10–20
Pineal tumours Germ cell tumour 2.5
Pineal parenchymal tumour 1.9
Suprasellar Craniopharyngioma 5.6
Optic hypothalamic glioma 3–6
Table 1. 
Common brain tumor types with location and frequency [5].
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4. Pathology and classification
Astrocytic tumors
• subependymal giant cell astrocytoma
• pilocytic astrocytoma
• Pilomyxoid astrocytoma
• diffuse astrocytoma
• pleomorphic xanthoastrocytoma
• anaplastic astrocytoma
• glioblastoma
• giant cell glioblastoma
• gliosarcoma
Oligodendroglial tumors
• oligodendroglioma
• anaplastic oligodendroglioma
Oligoastrocytic tumors
• oligoastrocytoma
• anaplastic oligoastrocytoma
Ependymal tumors
• subependymoma
Syndrome Gene 
locus
Gene Type of CNS tumour
NF type 1 17q11 NF1 Neurofibroma, meningioma, optic nerve glioma
NF2 22q12 NF2 Meningioma, schwannoma
TS 9q34, 
16p13
TSc1/TSC2 SEGA
VHL 3p35 VHL Haemangioblastoma
Li-Fraumani 17q13 p53 Glioma
Gorlin’s syndrome 9q31 PNET
Table 2. 
CNS tumour along with gene involved.
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• myxopapillary ependymoma
• ependymoma
• anaplastic epedymoma
Choroid plexus tumors
• choroid plexus papilloma
• atypical choroid plexus papilloma
• choroid plexus carcinoma
Other neuroepithelial tumors
• astroblastoma
• angiocentric glioma
• chordoid glioma of the third ventricle
Neuronal and mixed neuronal-glial tumors
• gangliocytoma
• ganglioglioma
• Anplastic ganglioglioma
• desmoplastic infantile astrocytoma and ganglioglioma
• dysembryplastic neuroepithelial tumor
• central neurocytoma
• extraventricular neurocytoma
• cerebellar liponeurocytoma
• paraganglioma of the spinal cord
• papillary glioneuronal tumor
• Rosette-forming glioneuronal tumor of the fourth ventricle
Pineal tumors
• pineocytoma
• pineal parenchymal tumor of intermediate differentiation
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• pineoblastoma
• papillary tumor of the pineal region
Embryonal tumors
• medulloblastoma
• CNS primitive neuroectodermal tumors
• atypical teratoid/rhabdoid tumor
Tumors of cranial and paraspinal nerves
• Schwannoma
• neurofibroma
• perineuroma
• malignant peripheral nerve sheath tumors
Meningeal tumors
• tumors of meningothelial cells
• mesenchymal tumors
• primary melanocytic lesions
• other neoplasms related to the meninges
• hemangioblastoma
Lymphoma and hematopoietic neoplasms
• malignant lymphoma
• plasmacytoma
• granulocytic sarcoma
Germ cell tumors
• germinoma
• embryonal carcinoma
• yolk-sac tumors
• choriocarcinoma
Current Cancer Treatment
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• teratoma
• mixed germ cell tumor
Tumors of the sellar region
• craniopharyngioma
• granular cell tumor of the neurohypophysis
• pituicytoma
• spindle cell oncocytoma of the adenohypophysis
Metastatic tumors
Modified from the WHO Classification of Tumors of the CNS, 2007 [7].
5. Clinical manifestations
The most common presenting symptoms of pediatric brain tumours are due 
to increased intracranial pressure. Headache and vomiting are two well-known 
symptoms associated with elevated intracranial pressure. Other signs, which reflect 
the increase in intracranial pressure, include drowsiness, confusion, nausea, sixth 
nerve palsy, papilledema, generalized seizures, and cognitive impairment. Focal 
signs and symptoms reflect the effect of the tumor on specific structures [8].
6. Radiological diagnosis
The features that play an important role in establishing the diagnosis are 
the age of the patient, location of the tumor and the imaging characteristics. 
Supratentorial tumors are more common in neonates and infants up to 2 years 
old, whereas infratentorial tumors are more common in children older than 
2 years. Although some tumors may be found both supra- and infratentorially. 
Tumors that are considered mostly supratentorial and intraaxial include astro-
cytomas, such as diffuse astrocytoma, anaplastic astrocytoma, pleomorphic 
xanthoastrocytoma (PXA), subependymal giant cell astrocytoma (SEGA), and 
glioblastoma multi-forme (GBM); oligodendrocytoma; primitive neuroectoder-
mal tumor (PNET); dysembryo-plastic neuroepithelial tumor (DNET); ganglio-
glioma; and desmoplastic infantile ganglioglioma. Some supratentorial extraaxial 
masses include arachnoid cysts, pineal region masses, and choroid plexus tumors.
Imaging is an important aspect in the management of patients with brain tumors. 
Imaging workup is largely based upon CT and MRI of the lesion. The technical 
development of CT and MRI methods has greatly enhanced brain tumor detection 
and sophisticated neuroimaging offers extra data by determining the metabolism and 
physiology of these lesions, which helps to diagnose and monitor brain neoplasms [9].
7. Computed tomography (CT)
CT scan plays an important role in establishing diagnosis of brain tumours. It 
can detect both blood and calcification. But some tumors, particularly tumors of 
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the brainstem, cerebellum, and suprasellar region as well as infiltrative tumors of 
the white matter, can be missed on CT neuroimaging [10].
7.1 MRI
It is the standard of care in children for imaging of suspected brain tumours.
The most useful imaging studies are T1-weighted sagittal images, gadolinium 
(Gd)-enhanced and unenhanced T1 axial images, T2-weighted axial images, and 
fluid-attenuated inversion recovery (FLAIR) sequences.
T1 images usually are better at demonstrating anatomy and areas of contrast 
enhancement. T2 and FLAIR images are more sensitive for detecting edema and 
infiltrative tumor.
7.2 Perfusion MRI
It plays an important role In differentiating low-grade tumors from high-grade 
tumors. It evaluates several hemodynamic parameters including cerebral blood 
volume (CBV), cerebral blood flow (CBF), and mean transit time (MTT); how-
ever, CBV has been shown to be the most useful parameter for the evaluation of 
intracranial masses [11].
7.3 Functional MRI
It detects functional areas of the brain by identifying areas of brain activation 
which have increased blood flow and changes in cerebral metabolism. It is used 
to determine the extent of resection as it can prevent any functional compromise. 
It is essential for planning function-preserving surgery in patients with brain 
tumours [12].
7.4 Magnetic resonance spectroscopy
It is useful in the evaluation of brain tumors in pediatric patients by helping 
determine the diagnosis, grade, and extent of the tumor. MRS can also differentiate 
radiation necrosis from tumor recurrence because normal metabolite levels after 
treatment favor edema and postsurgical changes [13].
7.5 Positron emission tomography (PET)
PET has clearly defined roles in primary brain tumor imaging. The FDG uptake 
of high-grade gliomas is more as compared with low-grade or well-differentiated 
neoplasms, and FDG-PET can be useful in making a distinction between low- and 
high-grade gliomas [14].
A few limitations of FDG-PET as a cerebral imaging agent are that normal brain 
tissue has high physiologic glucose metabolic rate producing a high FDG uptake 
which may mask smaller lesions. Another issue is in the detection of tumors with 
only modest increases in glucose metabolism, such as low-grade tumors which may 
be difficult to interpret [15]. 18F-fluoroethyl-L-thyrosin (18F-FET) is a promising 
radiotracer in determining the grade of brain tumors.
7.6 Cerebral fluid analysis
Chemistry and cytology of the cerebral fluid are used to determine the spread of 
the tumor. Findings may be important in subsequent treatment approaches.
Current Cancer Treatment
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8. Histologic confirmation of diagnosis
Histopathologic diagnosis of brain tumours is necessary for decision making 
regarding appropriate management. Stereotactic biopsy has emerged as a com-
paratively safe method of histological diagnosis and has significantly reduced the 
risks associated with brain biopsy [16]. Tissue sampling can be obtained either with 
stereotactic, open, or endoscopic procedures and, overall, provides.
Greater than 90% diagnostic yield, while it may be significantly lower (60–70%) 
in small (<1 cm3) and/or heterogeneous lesions [17].
8.1 Open biopsy
It is performed as an open technique by intraoperative neuronavigation. 
Typically, it is asserted for surface brain lesion, where hemostasis is critically vital 
or a surgical resection depending on frozen section histopathology is arranged. 
Although morbidity and mortality of open biopsy is more as compared to stereotac-
tic biopsy but neoplastic tissue yield is better and it influences the likelihood of an 
accurate diagnosis.
8.2 Stereotactic biopsy
It can be frame based and frameless. The frame-based method is focused on the 
fixation of the stereotactic frame on the patient’s head, whereupon the localizer is 
attached to the frame with many N-shaped posts. Under stereotactic circumstances, 
neuroimaging (CT, MRI, positron emission tomography [PET], etc.) is carried out 
and radiological information is transmitted to the specialized computer platform. 
The localizer posts are used as space coordinate references. For optimizing the 
target location and defining the ideal trajectory for biopsy, multiple pictures are 
combined.
The frameless biopsies are generally technically easier and require less prepara-
tory efforts in comparison to frame-based ones [18].
8.3 Endoscopic biopsy
It is recommended for intra- and periventricular tumors and can be done with or 
without frameless stereotactic guidance. The advantages of this technique are
1. direct visualization of the lesion
2. vascular structures can be seen during tissue sampling
3. more pathological specimens can be taken.
4. cerebrospinal fluid (CSF) samples can be taken for tumor marker analysis
In case obstructive hydrocephalus, third ventriculostomy can be simultaneously 
done [10].
Exception may be produced in chosen patients such as patients with known 
active systemic cancer and numerous lesions radiographically associated with brain 
metastases, patients with classic clinical and MRI results of brain stem glioma or 
optic nerve meningioma, HIV-positive patients with CT or MRI results consistent 
with primary CNS lymphoma and positive Epstein-Barr virus polymerase chain 
reaction in the CSF, or patients with secretory germ-cell tumors [19].
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9. Differential diagnosis
9.1 Infectious
Abscess-fever, acutely ill, ±systemic infection, ct findings show cyst cavity with 
smooth thin walls and restricted diffusion within cavity.
Cerebritis-fever, acutely ill, ±systemic infection, mri findings show diffuse T2 
change, no mass meningitis-diffuse enhancement of meninges on T1-weighted imaging.
9.2 Vascular
Infarct—MRI findings show Gray and white matter involvement, wedge like 
vascular distribution associated with restricted diffusion and low signal.
Subdural hematoma: anemia, retinal hemorrhage.
Bleeding—homogenous, clears quickly, residual hemosiderin ring.
Treatment-related necrosis—central hypodensity, edema, >6 months after 
radiation therapy or chemotherapy, metabolic scan shows low activity.
9.3 Neoplasm
Primary-solitary, no prior cancer.
Metastatic-multiple, prior cancer, ++edema, located at gray/white junction 
hydrocephalus: headache, vomiting, subarachnoid hemorrhage, Guillain-Barré 
syndrome tuberculoma: exposure to tuberculosis.
Pseudotumor cerebri: after otitis media, hormonal abnormalities.
10. General management
A focused history and symptom-based neurological examination is required 
which may be sufficient to raise brain tumor suspicion. Mental status assessment, 
cranial nerves, motor skills, sensory examination, coordination, and gait are key 
components of the neurological examination.
Preoperative laboratory testing which includes a complete blood cell count, renal 
and hepaic profile. A baseline ophthalmologic evaluation, including visual field 
testing and fundoscopic evaluation, is important in preoperative evaluations because 
most patients do not complain of visual field deficits at presentation. Glucocorticoids 
are used to control neurologic signs and symptoms caused by cerebral edema.
Although there is little evidence to support the use of corticosteroids with regard 
to overall outcome, corticosteroids can relieve headache, nausea, and vomiting and 
remain a generally accepted treatment.
In assessing a child suspected of having a brain tumor, a thorough neurological 
examination is of critical importance. Most kids diagnosed with a brain tumor have 
abnormal results on the presentation of neurological examination [20].
11. Neurosurgical procedure
Surgery remains the main treatment modality for most pediatric brain tumors. 
Depending on tumor type, the goals of surgical intervention are:
• Tissue diagnosis
• Re-establishment of normal CSF pathways
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• Diversion of CSF (shunting)
• Tumor debulking
• Complete tumor resection [5]
In the literature, overall surgical morbidity rates vary from 10 to 54%. The rates 
highly depend on the location of the tumour, grade and propensity to disseminate [21].
12. Radiotherapy
Radiotherapy plays an important role in the management of pediatric brain 
tumours. It can be used either as adjuvant treatment in case of resectable tumours 
or as a definitive management option in case of unresectable tumours [22].
The most common long term side effect of radiotherapy in pediatric age group 
is neurocognitive dysfunction and upto 20–60% patients suffer from neurocogni-
tive deficit as a long term sequelae of radiotherapy [23]. Sophisticated radiotherapy 
techniques are warranted for to avoid future negative impacts of radiation on 
pediatric brain development.
Use of better immobilization and more suitable imaging techniques like high-
resolution brain imaging with computed tomography (CT) and magnetic resonance 
imaging (MRI) to accurately define the tumour limits and precisely assess the 
normal brain structures has greatly improved the degree of efficacy achieved by 
radiotherapy without increasing the side effects [24].
Technological advancements like use of conformal radiotherapy allows high 
radiation dose distributions within targeted tissues while simultaneously attempt-
ing to reduce dose to surrounding normal tissues. Conformal radiotherapy can 
be accomplished through a variety of techniques, including intensity-modulated 
radiotherapy (IMRT), stereotactic radiotherapy and proton beam therapy.
IMRT has shown promise in the treatment of a number of disease sites and is 
now being investigated in the use of pediatric tumors to reduce long-term toxicity. 
Stereotactic technique has the ability to reduce the treatment volume as it delivers 
highly conformal radiation to brain tumours and minimum dose to surrounding 
brain tissue. It can be delivered as stereotactic radiosurgery in which the entire dose 
is delivered as a single fraction or as fractionated stereotactic radiotherapy (FSRT) 
in which the treatment is delivered over weeks with multiple daily fractions. Only 
small margins of several millimeters are used for brain tumors, greatly reducing the 
volume of normal brain parenchyma receiving high doses of radiation.
13. Chemotherapy
High-dose chemotherapy with or without support by autologous stem cell 
transplantation, especially in children below the age of 3 years [25].
Palliative chemotherapy:
• May induce transient remission
• Increases the quality of life
• The benefits of chemotherapy or other treatments must be balanced by consid-
eration of the toxicities
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14. Special tumor types astrocytic tumor
Astrocytomas are the most common pediatric brain tumors, accounting for 7–8% 
of all childhood cancers [26]. Approximately 40% of all pediatric brain tumours are 
low grade astrocytoma, whereas most common primary CNS malignancy in adults 
being high grade astrocytoma [7]. Pediatric brain tumors are typically infratentorial, 
localized predominantly in the posterior fossa and brainstem [27].
Pediatric astrocytic tumours are further sub-classified by WHO grades (Table 3).
14.1 Genomic alterations low grade glioma
1. Most common genomic modification in cases of pilocytic astrocytoma involves 
activation of BRAF and the ERK/MAPK pathway [29]
2. Alternative BRAF gene fusions, RAF1 rearrangements, RAS mutations, and 
BRAF V600E point mutations are less commonly observed in such cases [30].
3. Presence of the BRAF-KIAA1549 fusion gene shows better progression-free 
survival (PFS) and overall survival (OS) [31].
4. Other pediatric low-grade gliomas (e.g., pilomyxoid astrocytoma) are also 
associated with BRAF activation through the BRAF-KIAA1549 fusion [32].
5. In 53% pediatric grade II diffuse astrocytomas, the most common alterations 
reported are rearrangements in the MYB family of transcription factors [33].
Children having mutation in one of two tuberous sclerosis genes (TSC1/
hamartin or TSC2/tuberin) are at a risk of developing Subependymal giant cell 
astrocytomas, cortical tubers, and subependymal nodules, as either of these 
mutations results in activation of the mammalian target of rapamycin (mTOR) 
complex 1 [34].
14.2 High grade glioma
The following pediatric high-grade glioma subgroups were identified on the 
basis of their DNA methylation patterns, and they show distinctive molecular and 
clinical characteristics:
1. Histone K27-mutation: H3.3 (H3F3A) and H3.1 (HIST1H3B and, rarely, 
HIST1H3C) mutation at K27. These cases occur predominantly in mid 
Astrocytic tumour Grade
Subependymal giant cell astrocytoma
Pilocytic astrocytoma
I
Pilomyxoid astrocytoma
Diffuse astrocytoma
Pleomorphic xanthoastrocytoma
II
Anaplastic astocytoma III
Glioblastoma giant glioblastoma gliosarcoma IV
Table 3. 
WHO grades of pediatric astrocytic tumours [28].
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childhood (median age, approximately 10 years). They are almost exclusively 
midline, usually present in the thalamus, brain stem, and spinal cord, and 
carry a very poor prognosis.
H3.3K27M cases are usually present between ages 5 and 10 years, accounting 
for approximately 60% of cases in the midline and pons. The prognosis for 
H3.3K27M patients is extremely poor, with a median survival of <1 year [35].
H3.1K27M cases present at a younger age than H3.3K27M cases and are 
approximately 5 times less frequent. These cases have a slightly more favorable 
prognosis than do H3.3K27M cases (median survival, 15 vs. 11 months).
2. H3.3 (H3F3A) mutation at G34: The H3.3G34 subtype is associated with 
mutations in TP53 and ATRX which show widespread hypomethylation across 
the whole genome. It is common in older children and young adults (median 
age, 14–18 years) and arises exclusively in the cerebral cortex [36].
About 5% pediatric high-grade gliomas have IDH1-mutation. They are almost 
exclusively common in older adolescents (median age in a pediatric population, 
16 years).
Pleomorphic xanthoastrocytoma (PXA)-like: Approximately 10% of pediat-
ric high-grade gliomas have DNA methylation patterns that are PXA-like [37].
15. Treatment
15.1 Low-grade astrocytomas
Low-grade astrocytomas (grade I [pilocytic] and grade II) spread by direct 
extension; dissemination to other CNS sites is uncommon. Complete excision is the 
treatment of choice and the outcome is favorable especially if the tumor is circum-
scribed [38].
Markers of poor prognosis for childhood low-grade astrocytomas are:
1. Young age.
2. Diffuse histology, especially IDH-mutant.
3. Inability to obtain a complete resection.
4. Diencephalic syndrome.
5. Intracranial hypertension at initial presentation [39].
6. Metastases.
15.2 High-grade astrocytomas
Gross total resection is recommended for anaplastic astrocytomas. Local inva-
sion of adjacent brain tissue is relatively common. Prognosis is poor for younger 
patients.
Depending on the degree of resectability, other treatment options are:
• Radiotherapy usually causes short-term and partial remission.
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• Multiagent chemotherapy improve survivability with variable long-term 
remission
• Effective drugs alone or in combination: cisplatin, carboplatin, cyclophospha-
mide, ifosfamide, etoposide, topotecan, procarbazine, temozolomide, lomus-
tine (CCNU), carmustine (BCNU) [40].
15.3 Optic-hypothalamic glioma
Optic pathway-hypothalamic gliomas are rare astrocytic tumors that are more 
among young children. They comprise approximately 2% of all central nervous 
system tumors and account for 3–5% of pediatric intracranial tumors.
OPG was classified by Dodge et al. into the following three stages: (A) limited to 
the optic nerve; (B) involving optic chiasma (with or without extension to the optic 
nerve) and (C) involvement of hypothalamus and other structures [41].
The tumours do not produce symptoms at an early stage. The symptoms can be 
due to impingement on optic nerve or chiasma which leads to visual disturbances, 
involvement of hypothalamus causing endocrinopathies and hypothalamic dys-
function such as the diencephalic syndrome. It can also cause csf outflow block 
leading to hydrocephalus [42].
Surgery has a limited role in the treatment of these tumours as they lie close to 
critical structures. It is usually limited to establishing a histopathological diagnosis or 
debulking in case of large tumours. Although Gross total resection of low-grade glioma 
is strongly associated with improvement of both OS and PFS but Aggressive resection, 
often leads to blindness, hypothalamic damage and cognitive dysfunctions [43].
15.3.1. Chemotherapy
Carboplatin and Vincristine is the most frequently recommended first-line 
chemotherapy, and it is considered to be the standard treatment of OPG [44].
15.3.2. Radiation
Radiotherapy is considered as a treatment option for OPG but at a cost of long 
term complications of neurocognitive dysfunction and visual disturbances [45]. 
Radiation may therefore be useful for an adjuvant treatment in the case of che-
motherapy refractory tumors. Prognosis depends upon the age of the patient and 
location of the tumour. Young age and tumour located in optic pathway and hypo-
thalamus are considered as poor prognostic factors.
16. Brain stem tumors
Pediatric brainstem gliomas occur as two major types:
Focal brainstem gliomas, usually WHO grade I–II tumors.
Diffuse intrinsic pontine gliomas, range from WHO grade III–IV [46]. They usu-
ally arise in the medulla, pons, or midbrain.
Focal brainstem gliomas (FBSG): constitutes approximately 20% of pediatric 
brainstem gliomas and usually occur outside the pons. Most are either pilocytic 
astrocytomas (grade I) or fibrillary astrocytomas (grade II) [47].
FBSG is usually insidious in nature and the symptoms are related to site of 
tumour location. Most common symptoms include neck stiffness, cranial nerve 
deficit and contralateral hemiparesis.
Current Cancer Treatment
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Hydrocephalus is uncommon except in posterior exophytic tumours [48].
On MRI, FBSG can be seen with defined borders, lack of surrounding edema, 
iso- or hypointensity on T1, hyperintensity on T2, and homogeneous contrast 
enhancement [49].
Surgical resection has emerged as treatment of choice due to development of 
modern imaging and neurosurgical techniques. FBSG confined to cervicomedullary 
region and/ or exophytic are amenable to complete resection [50] even with incom-
plete resection, the long-term prognosis for this patient population is excellent.
Chemotherapy can be used as adjuvant after complete or incomplete tumour 
resection or in cases of tumour progression. Most commonly used chemotherapy 
regimen is vincristine and carboplatin, which achieves at least stable disease in 
68–75% of patients, and a positive response in about 40% [51]. Other regimens 
comprise of 6-thioguanine, procarbazine, lomustine, and vincristine (TPCV), 
vinblastine [52], bevacizumab with or without irinotecan [53], everolimus [54], and 
a metronomic, oral, anti-angiogenic regimen consisting of celecoxib, thalidomide, 
fenofibrate, cyclosphosphamide, and etoposide [55].
Radiation therapy (RT), while often effective in inducing prolonged remission 
in FBSG, has severe associated toxicities, especially for young children.
Diffuse intrinsic pontine gliomas (DIPG) account for approximately 80% of 
pediatric brainstem tumors and with male to female ratio as 1:1. It is more common in 
younger age group. These tumors are almost always highly malignant and fatal [56].
The patients have DIPG have a more lethal and shorter duration course than 
FBSG as it is more aggressive disease. Patients usually present within 3 months of 
tumour development. The most common symptoms are cranial nerve palsies, most 
often of cranial nerves VI and VII but sometimes including III, IV, IX, and/or X, as 
well as long tract signs like hemiparesis.
On CT scan, DIPG appears isodense or hypodense, without calcifications. On 
MRI, DIPG is most often hypointense on T1 and hyperintense on T2. Contrast 
enhancement is variable in both modalities but is usually not diffusely uniform, as it 
often is in FBSG. Diffusion is most often increased [57].
Apart from medical management starting with dexamethsone, aimed to relieve 
neurological symptoms, not many treatment options are available. RT is the only 
therapy proven to prolong survival of patients, that too it is palliative in nearly 
every case.
Currently, RT is given at a dose of 54–59 Gy at 1.8 Gy daily fractions for 
30–33 days locally, to the area of the tumor plus a 1–2 cm surrounding margin.
Chemotherapy has not shown any benefit in concurrent, adjuvant or palliative form.
The prognosis for DIPG patients remains devastatingly poor. Recent studies 
have shown median progression free survival of 7 months and an overall survival of 
9–11 months. In one large series, 77% of patients responded to treatment, and it was 
for a transient period as the therapy is rarely curative [58]. Poor prognostic marker 
at diagnosis or post treatment is the presence of leptomeningeal disease and no 
studies confirm these patients will benefit from craniospinal irradiation [59].
17. Medulloblastoma
Medulloblastoma is the second most common central nervous system tumour of 
childhood, most commonly occurring between 4 and 7 years of age. It usually arises 
from the roof of the fourth ventricle or from the midline structures of the brain [60].
Etiology: for most patients the etiology is unknown but is associated with certain 
genetic disorders (i.e., Gorlin syndrome, Turcot syndrome, Li-Fraumeni syndrome, 
Rubinstein-Taybi syndrome, and ataxia telangiectasia) [61].
15
An Overview of Pediatric CNS Malignancies
DOI: http://dx.doi.org/10.5772/intechopen.88189
It has the propensity to disseminate along the cerebrospinal fluid (CSF) path-
way, and metastatic disease at diagnosis is found in approximately 30% of patients. 
Spread outside the central nervous system (CNS) is very rare at diagnosis.
WHO classification 2007 categorises medulloblastoma as grade IV neoplasms 
under the group of embryonal neuroepithelial tumours. There are several histo-
pathological subtypes of medulloblastoma. In addition to classic variant, other 
subtypes include desmoplastic/nodular medulloblastoma, medulloblastoma with 
extensive nodularity (MBEN), anaplastic medulloblastoma, and large cell medul-
loblastoma [25].
Molecular subgrouping of medulloblastoma divides it into four distinct sub-
groups which are identified on the basis of transcriptional profiling studies as wing-
less (Wnt), sonic hedgehog (Shh), Group 3, and Group 4 (Table 4). Each subgroup 
is defined by a unique set of demographic and clinical features, genetics, and gene 
expression [63].
Signs and symptoms: usually due to increased intracranial tension, hydro-
cephalus and cerebellar dysfunction, and comprise vomiting, macrocephalus, loss 
of developmental achievements in infants, and headache, vomiting, ataxia, and 
cranial nerve palsy in older patients.
Management: biopsy has no role in the diagnosis if it is radiographically sup-
ported. Medulloblastomas have distinct imaging characteristics on both computed 
tomography (CT) and magnetic resonance imaging (MRI). Since 75% of medul-
loblastomas arise from the cerebellar vermis, they tend to protrude into the fourth 
ventricle in pediatric age group. On CT scan, in case of young patients, efface-
ment of the fourth ventricle is seen along with its dilatation which is secondary to 
obstructive hydrocephalus. In case of older patients, they are most commonly seen 
as a hyperdense mass arising from the vermis with cyst formation or necrosis.
On MRI, medulloblastomas are hypointense to grey matter on T1-weighted 
imaging with heterogeneous gadolinium enhancement on T2-weighted imaging 
WNT SHH GROUP 3 GROUP 4
Percentage 10% 30% 25% 35%
Age Children and 
adults
Mainly infants 
and adults
Mainly infants 
and children
Mainly children 
and adults
Somatic 
nucleotide 
variant
CTNNB1, 
DDX3, 
SMARCA4, 
CREBBP, TP53*
PTCH1, SUFU, 
SMO, TERT, 
IDH1, TP53, 
KMT2D
SMARCA4, 
CTDNEP1, 
KMT2D, KBTBD4
KDM6A, 
KMT2C
Somatic 
copy number 
alterations
MYCN, GLI2 MYC, PVT1, 
OTX2, GFI1/1b
SNCAIP, 
MYCN, CDK6, 
GFI1/1b
Cytogenetics Monosomy 6 Gain of 3q, 9p, 
loss of 9q, 10q, 
14q, 17p
i17q, loss of 8, 10q, 
11, 16p, 17p, gain 
of 1q, 7, 17q, 18q
i17q, loss of 8p, 
11p, X, gain of 
7q, 18q
Prognosis Very good Intermediate Poor Intermediate
Incidence of 
metastasis
5–10% 10–15% 40–45% 35–40%
Pattern of 
relapse
Local and distal Local Distal Distal
*It shows characterstics of each molecular subgroups of medulloblastoma.
Table 4. 
Molecular subgroups of medulloblastoma [62].
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they appear iso- to hyperintense to grey matter and can seem heterogeneous due to 
cyst formation, calcification and necrosis. MR spectroscopy shows elevated choline 
peaks and decreased creatine and N-acetyl acetate peaks, with occasional elevation 
in lactic acid and lipid peaks [64].
Maximal safe resection is recommended in all medulloblastoma patients. Apart 
from surgical resection, the current standards of radiation therapy and medical 
management vary by extent of disease and age of the patient. Radiation therapy can 
be used to decrease the risk of recurrence but neurocognitive effects of radiation 
therapy have to be considered by weighing the risk benefit ratio.
Patients who are 3 years of age or older are stratified as either “average-risk” or 
“high-risk” depending upon postoperative residual tumor volume and the presence 
or absence of disseminated disease (Table 5).
Patients who are younger than 3 years of age, are treated without upfront radiation 
therapy due to the unacceptably high risk of severe neurocognitive impairment [65].
In the postoperative setting, average-risk patients >3 years old were previously 
treated with 36 Gy craniospinal irradiation (CSI) but now a boost to the posterior 
fossa is given for a total dose of 54 Gy due to the high rate of relapse within the 
posterior fossa. CSI dose of 23.4–24 Gy can be given with the addition of chemo-
therapy as supported by Studies conducted by the International Society of Pediatric 
Oncology (SIOP) and the Children’s Oncology Group [66].
Current recommendations for post-radiation chemotherapy in average-
risk patients include approximately 1 year of therapy consisting of 8 cycles at 
6-week intervals of cisplatin, lomustine (CCNU), and vincristine. The St. Jude 
Medulloblastoma-96 trial has demonstrated a similar event-free survival of 83% 
when an alkylator-based, dose-intensive chemotherapy regimen consisting of four 
4-week cycles of cyclophosphamide, cisplatin, and vincristine with autologous stem 
cell rescue was employed following each cycle [67].
For high risk medulloblastoma cases in children 3 years or older, the treatment is 
surgical resection followed by post-operative “standard dose” RT (36 Gy CSI with a 
boost to both the posterior fossa and focal sites of metastatic disease to 55.8 Gy) as 
well as adjuvant chemotherapy.
The most common adverse effect of craniospinal irradiation in children <3 years 
age is neurocognitive deficit. Therefore radiotherapy is either delayed or omitted in 
this subset of patients. There is evidence that regimens consisting of surgery and 
chemotherapy without RT can be successful in specific subsets of medulloblas-
toma patients. Outcomes in patients with relapsed disease are generally poor, with 
reported 5-year survival rates of approximately 25% [68]. Unfavorable prognostic 
factors include large tumor, csf dissemination, age <4 years, subtotal tumour resec-
tion (<90%), chromosome deletion 17p, c-MYC amplification.
18. Atypical teratoid rhabdoid tumors (ATRT)
Atypical teratoid rhabdoid tumours (ATRTs) are the most common malig-
nant central nervous system tumours in children ≤1 year of age and represent 
Average 
risk
High 
risk
Residual postoperative tumour volume <1.5 cm2 ≥1.5
CSF cytology/evidence of disease dissemination on MRI in brain and spine Absent Present
Table 5. 
Risk stratification of medulloblastoma.
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approximately 1–2% of all pediatric brain tumours [69]. ATRT is a primarily 
monogenic disease characterized by the bi-allelic loss of the SMARCB1 gene, which 
encodes the hSNF5 subunit of the SWI/SNF chromatin remodeling complex [70]. 
The most common site of ATRT is posterior fossa, mainly cerebellar hemispheres 
(⅔ cases) [71]. It can also occupy fourth ventricle causing its displacement and 
compression by invading the adjacent cisternal space.
In patients <3 years of age, the most common treatment is high dose chemother-
apy with autologous stem cell rescue, so that CSI can be avoided in young patients as 
poor outcomes are seen due radiotherapy induced neurocognitive impairment [72].
Despite using chemotherapy and radiotherapy as treatment options, ATRT has poor 
survival outcomes due to early dissemination and progression of the tumours [73].
19. Pineal tumors
Incidence of pineal tumours in children ranges from 2.7 to 11% [74]. Germ cell 
tumors (GCTs) account for nearly 50–75% of all pineal tumors [75], Pineal paren-
chymal tumors account for nearly 15–27% of pineal tumors and include pineo-
cytoma, parenchymal tumor of intermediate differentiation, pineoblastoma and 
papillary tumor of the pineal region. Other described pineal tumors include glioma, 
ependymoma and atypical teratoid or rhabdoid tumors [76].
Preferred treatment strategy of different pineal region tumours [77] (Table 6).
20. Ependymoma
Ependymoma accounts for 6–12% of all brain tumors in childhood. It represents 
the third most common brain tumor in this age group, following astrocytomas and 
medulloblastomas [78]. Ependymoma are classified according to the WHO patho-
logical grading system (Table 7).
They are usually located in or adjacent to ventricles within the parenchyma. In 
pediatric age group majority of intracranial ependymoma are located at infratento-
rial region in posterior fossa, usually arising at the floor of fourth ventricle.
Prognostic factors include tumor location, size, surrounding anatomical structures, 
tumor appearance, genotype, comorbidities, clinical symptoms, and patient age [79].
Pineoblastoma <3 years Radiotherapy is avoided
Induction chemotherapy followed by consolidation myeloablative 
chemotherapy with stem cell rescue
Pineoblastoma 3–6 years Induction chemotherapy followed by consolidation myeloablative 
chemotherapy with stem cell rescue
Pineoblastoma >6 years Full-dose craniospinal irradiation (36 Gy) plus boost (total of 54 Gy) to the 
primary site along with concomitant daily carboplatin and weekly vincristine 
followed by 6 cycles of maintenance chemotherapy
Germinoma Four cycles of chemotherapy with carboplatin and etoposide followed by whole 
ventricular irradiation to 23.4 Gy plus a boost to the primary site to a total dose 
of 30 Gy
Non-germinomatous 
germ cell tumour
Six cycles of chemotherapy with carboplatin, ifosfamide and etoposide 
followed by 30 Gy whole ventricular irradiation plus a boost to the primary site 
to a total dose of 50 Gy in patients with a radiographic and serologic complete 
response
Table 6. 
Treatment strategies of different pineal tumours.
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The current treatment of choice for pediatric patients with cranial ependymoma 
is resection, if possible, followed by radiation therapy alone [80].
21. Craniopharyngioma
They are low histological grade (WHO I) tumours which arise from epithelial 
remnants of rathke’s pouch. They are usually located in sellar or parasellar location 
with an overall incidence of 0.5–2.0 new cases per million of the population per 
year, and constitute 1.2–4.0% of all childhood intracranial tumors.
Symptoms depend upon the location of the tumour:
Craniopharyngimas can present with nonspecific symptoms like headache and 
nausea due to increased intracranial pressure.
Intrasellar lesions can compress the pituitary gland and hypothalamus involving 
the hypothalamic-pituitary axes in 52–87% cases, leading to endocrine defects, par-
ticularly deficits in the secretion of growth hormone (75% of cases), gonadotropins 
(40%), adrenocorticotropic hormone (25%) and TSH (25%) [81].
Prechiasmal lesions may compress the optic pathway, leading to visual field 
cuts, decreased central visual acuity or vision impairment (62–84% of cases in 
children).
Retrochiasmal lesions may grow into the third ventricle and cause hydrocepha-
lus or compress the optic tracts.
Craniopharyngiomas can cause direct impingement of brain parenchyma and 
produce neurological deficit.
In case of localized tumours the preferred choice of treatment is complete 
resection with preservation of visual, pituitary and hypothalamic function [82]. 
In case of incomplete resection, there are chances of residual tumour progression 
in 71–90% of patients, whereas the rate of progression after incomplete resection 
followed by radiotherapy is 21%. Therefore radiotherapy is recommended after 
surgical resection [83].
22. Conclusion
Since brain tumours are a leading cause of morbidity and mortality among 
children, the focus lies on how effectively they can be treated. Surgery plays a major 
role and can be curative in a number of tumours including pilocytic astrocytoma. 
Radiotherapy is curative in cases of PNET and ependymoma.
The survival and long-term outcome of patients with brain tumors will continue 
to enhance with future advances in nonsurgical methods, molecular and transla-
tional oncology research. For longer survival and reduced morbidity, new molecu-
lar diagnostics and new therapies such as immunotherapy, gene therapy and stem 
cell therapy may be promising.
Tumour type Grade
Subependymoma (benign) myxopapillary ependymoma I
Ependymoma II
Anaplastic ependymoma III
Table 7. 
WHO pathological grades of ependymoma.
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